“The time has come for a nonprofit pharmaceutical company focused on decreasing naloxone’s costs and increasing its availability as an over-the-counter product.
A nonprofit pharmaceutical company will not be a panacea for America’s opioid crisis, nor for the ongoing struggle with the high prices of many drugs. Indeed, for-profit pharmaceutical companies are central to America’s leading role in medical innovation. Profits help to ensure that innovation is rewarded and drug development continues to be an attractive investment despite the complexity and challenge of finding and developing new drugs.
To succeed in getting naloxone into the hands of everyone who might benefit from it, money from nonprofit foundations with an interest in public health and reducing the scourge of opioids must be combined with drug development expertise and a nonprofit mission to bring naloxone to every drug store in America. It is an idea whose time has come. As lives are lost every day from opioid overdoses, low cost, over-the counter naloxone is now an urgent priority for a nonprofit pharmaceutical company.”
Michael R Hufford, PhD
Co-Founder & Chief Executive Officer